These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 31918567)

  • 1. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.
    Fox KM; Tai MH; Kostev K; Hatz M; Qian Y; Laufs U
    Clin Res Cardiol; 2018 May; 107(5):380-388. PubMed ID: 29273856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis.
    Pohl SB; Engelbertz C; Reinecke H; Malyar NM; Meyborg M; Brix TJ; Varghese J; Gebauer K
    Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1670-1680. PubMed ID: 38664125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice.
    Ferrières J; Gorcyca K; Iorga ŞR; Ansell D; Steen DL
    Clin Ther; 2018 Sep; 40(9):1484-1495.e22. PubMed ID: 30126705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
    Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
    Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population.
    Steen DL; Khan I; Becker L; Foody JM; Gorcyca K; Sanchez RJ; Giugliano RP
    Clin Cardiol; 2017 Mar; 40(3):155-162. PubMed ID: 28026031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol.
    Harrison TN; Scott RD; Cheetham TC; Chang SC; Hsu JY; Wei R; Ling Grant DS; Boklage SH; Romo-LeTourneau V; Reynolds K
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):397-404. PubMed ID: 30062465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
    Teramoto T; Uno K; Miyoshi I; Khan I; Gorcyca K; Sanchez RJ; Yoshida S; Mawatari K; Masaki T; Arai H; Yamashita S
    Atherosclerosis; 2016 Aug; 251():248-254. PubMed ID: 27419905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
    Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
    Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.